NTRK2 and adenocarcinoma: We previously showed that BDNF or TrkB could play a role as biomarkers for reduced survival in other malignancies, such as oral squamous cell carcinoma [46] and melanoma [47], and this was further demonstrated in other adenocarcinomas, such as breast [48] and lung [49].